Cargando…

Antiphospholipid syndrome

Antiphospholipid syndrome is diagnosed when arterial or venous thrombosis or recurrent miscarriages occur in a person in whom laboratory tests for antiphospholipid antibodies (anticardiolipin antibodies and/or lupus anticoagulant and/or anti-beta 2-glycoprotein I) are positive. Despite the strong as...

Descripción completa

Detalles Bibliográficos
Autores principales: Espinosa, Gerard, Cervera, Ricard
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2656223/
https://www.ncbi.nlm.nih.gov/pubmed/19090981
http://dx.doi.org/10.1186/ar2536
_version_ 1782165480034795520
author Espinosa, Gerard
Cervera, Ricard
author_facet Espinosa, Gerard
Cervera, Ricard
author_sort Espinosa, Gerard
collection PubMed
description Antiphospholipid syndrome is diagnosed when arterial or venous thrombosis or recurrent miscarriages occur in a person in whom laboratory tests for antiphospholipid antibodies (anticardiolipin antibodies and/or lupus anticoagulant and/or anti-beta 2-glycoprotein I) are positive. Despite the strong association between antiphospho-lipid antibodies and thrombosis, their pathogenic role in the development of thrombosis has not been fully elucidated. Novel mechanisms involving both the complement pathway and micro-particles have been described. The knowledge of these new pathogenic approaches might identify novel therapeutic targets and therefore may improve the management of these patients.
format Text
id pubmed-2656223
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-26562232009-06-15 Antiphospholipid syndrome Espinosa, Gerard Cervera, Ricard Arthritis Res Ther Review Antiphospholipid syndrome is diagnosed when arterial or venous thrombosis or recurrent miscarriages occur in a person in whom laboratory tests for antiphospholipid antibodies (anticardiolipin antibodies and/or lupus anticoagulant and/or anti-beta 2-glycoprotein I) are positive. Despite the strong association between antiphospho-lipid antibodies and thrombosis, their pathogenic role in the development of thrombosis has not been fully elucidated. Novel mechanisms involving both the complement pathway and micro-particles have been described. The knowledge of these new pathogenic approaches might identify novel therapeutic targets and therefore may improve the management of these patients. BioMed Central 2008 2008-12-15 /pmc/articles/PMC2656223/ /pubmed/19090981 http://dx.doi.org/10.1186/ar2536 Text en Copyright © 2008 BioMed Central Ltd
spellingShingle Review
Espinosa, Gerard
Cervera, Ricard
Antiphospholipid syndrome
title Antiphospholipid syndrome
title_full Antiphospholipid syndrome
title_fullStr Antiphospholipid syndrome
title_full_unstemmed Antiphospholipid syndrome
title_short Antiphospholipid syndrome
title_sort antiphospholipid syndrome
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2656223/
https://www.ncbi.nlm.nih.gov/pubmed/19090981
http://dx.doi.org/10.1186/ar2536
work_keys_str_mv AT espinosagerard antiphospholipidsyndrome
AT cerveraricard antiphospholipidsyndrome